Value
6.1/10data confidence 83%| Component | Sub-score |
|---|---|
| P/S | 6.7 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 4.7 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 26.6x
- ▸PEG: 0.06
PTCT · Why this verdict
Why PTC Therapeutics (PTCT) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score6.5/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
PTC Therapeutics shows exceptional momentum with an RSI of 71, rising OBV, and a 2.8x average volume surge, but is constrained by cash-burning operations with free cash flow at -51% of revenue, low business quality, and an asymmetry ratio of only 0.52 that fails the minimum entry threshold.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stock is exhibiting strong upward momentum with RSI at 71 (overbought), confirmed volume accumulation from rising OBV, a 2.8x average volume surge on up moves, and a MACD in bullish territory, with the stock trading above its 200-day moving average. Momentum breakdown | Price sustains above its 200-day moving average for at least 6 months without a confirmed reversal below. | ↑Improving |
| CounterAn RSI of 71 signals overbought conditions, and with the stock already above its analyst price target, the near-term risk of a mean-reversion pullback is elevated. | ||
Free cash flow is -51% of revenue and the company carries no competitive moat, resulting in a business quality score of 3.4/10 that falls below the minimum investable threshold of 4.0, indicating the business is not yet self-sustaining. Quality breakdown | Free cash flow improves to above -20% of revenue within 12 months as the company scales revenue faster than costs. | →Stable |
| CounterBiotechnology companies routinely burn cash during clinical development phases, and the current burn rate may be appropriate given the company's pipeline stage. | ||
The company beat analyst estimates in 3 of the last 4 quarters, including a 93% beat in the most recent quarter where actual EPS came in at -$0.03 versus an estimate of -$0.44, suggesting the losses are narrowing faster than expected. Earnings | Quarterly EPS loss narrows to less than -$0.10 within the next 2 quarters. | →Stable |
| CounterThe one miss in the prior year involved a -1,097% negative surprise, a massive earnings shortfall that highlights the volatility inherent in biotech reporting and the risk of sudden reversals. | ||
Short interest stands at 17% of float with high implied volatility of 90%, and the stock is trading above its options max pain level of $55 by more than 40%, creating meaningful squeeze and violent pullback risk simultaneously. Risk breakdown | Short interest falls below 10% within 12 months as the investment thesis is confirmed and shorts cover. | →Stable |
| CounterHigh short interest in a cash-burning biotech with below-floor business quality may reflect informed short sellers with visibility into execution risk, not just speculative positioning. | ||
The stock is exhibiting strong upward momentum with RSI at 71 (overbought), confirmed volume accumulation from rising OBV, a 2.8x average volume surge on up moves, and a MACD in bullish territory, with the stock trading above its 200-day moving average.
↑ImprovingMomentum breakdown
- Expectation
- Price sustains above its 200-day moving average for at least 6 months without a confirmed reversal below.
CounterAn RSI of 71 signals overbought conditions, and with the stock already above its analyst price target, the near-term risk of a mean-reversion pullback is elevated.
Free cash flow is -51% of revenue and the company carries no competitive moat, resulting in a business quality score of 3.4/10 that falls below the minimum investable threshold of 4.0, indicating the business is not yet self-sustaining.
→StableQuality breakdown
- Expectation
- Free cash flow improves to above -20% of revenue within 12 months as the company scales revenue faster than costs.
CounterBiotechnology companies routinely burn cash during clinical development phases, and the current burn rate may be appropriate given the company's pipeline stage.
The company beat analyst estimates in 3 of the last 4 quarters, including a 93% beat in the most recent quarter where actual EPS came in at -$0.03 versus an estimate of -$0.44, suggesting the losses are narrowing faster than expected.
→StableEarnings
- Expectation
- Quarterly EPS loss narrows to less than -$0.10 within the next 2 quarters.
CounterThe one miss in the prior year involved a -1,097% negative surprise, a massive earnings shortfall that highlights the volatility inherent in biotech reporting and the risk of sudden reversals.
Short interest stands at 17% of float with high implied volatility of 90%, and the stock is trading above its options max pain level of $55 by more than 40%, creating meaningful squeeze and violent pullback risk simultaneously.
→StableRisk breakdown
- Expectation
- Short interest falls below 10% within 12 months as the investment thesis is confirmed and shorts cover.
CounterHigh short interest in a cash-burning biotech with below-floor business quality may reflect informed short sellers with visibility into execution risk, not just speculative positioning.
Per-dimension breakdown
Quality
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 1.6 |
| Gross margin | 6.0 |
| Op margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 9.6 |
| FCF quality | 0.0 |
| Moat | 6.2 |
| Piotroski F | 8.9 |
- ▸Cash-burning: FCF -28% of revenue
- ▸Strong Piotroski F-Score: 8/9
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 101% YoY
Momentum
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 4.0 |
| Volume | 2.7 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -2.9%/30d — confirmed downtrend
Sentiment
7.7/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.3 |
| Price target | 9.6 |
| erm sentiment | 6.0 |
- ▸Analyst upside: 55%
Insider
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Notable insider selling — $8,457,867 (0.161% of mkt cap)
- ▸Institutions accumulating
Peer rank
6.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 7.1 |
| quality rank | 4.5 |
| growth rank | 8.3 |
- ▸Industry growth leader
Technical
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.8 |
| support resistance | 3.8 |
| 52w position | 3.9 |
Risk (lower is worse)
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.3 |
| days to cover | 4.0 |
| volatility | 3.6 |
| put call | 0.7 |
| implied vol | 2.0 |
| beta | 10.0 |
- ▸Elevated put/call: 1.89
- ▸High IV: 68%
- ▸Concentration risks: 2 MED (10-K Item 1A)
Catalyst
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 6.5 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 7.1 |
- ▸Strong earnings: 3B/1M
- ▸Earnings today
How the verdict was assembled
Engine trigger
Earnings today. Wait until post-earnings.
Engine technical detail
verdict_path:
L3:NEWS_BLOCK|ENTRY_STICKY:WITHIN_BANDPassed (6)
- MOMENTUM:6.2>=5.5
- ASYMMETRY:5.6>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- EARNINGS_PROXIMITY:0d<=7d
Warning (2)
- DEATH_CROSS:momentum=6.2>=5.0 recovering
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
5.59
Upside
+39.7%
Downside
7.1%
Sizing output
STARTER
SetupRecovery — Death cross but MACD improving, RSI 51
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
A recent news event triggered an L3 news-block on the verdict path. Trigger: Earnings today. Wait until post-earnings. The 10-dimension scores remain Growth at 10.0 (strongest), but EARNINGS_PROXIMITY:0d<=7d also fails — the news block is the proximate trigger, not the sole driver.
The strongest dimensions are Growth at 10.0, Sentiment at 7.7, and Catalyst at 6.3; the weakest are Technical at 3.8, Risk (lower is worse) at 3.9, and Quality at 5.3. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 5.59 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Price Momentum Surge
Trip ifPrice falls below the 200-day moving average and RSI drops below 40 within 30 days of each other.
- P2Cash Burn Quality Deficit
Trip ifFree cash flow burn exceeds 70% of quarterly revenue for 2 consecutive quarters.
- P3Earnings Improvement Trajectory
Trip ifEPS surprise falls below -50% in at least 2 of the next 4 quarters.
- P4High Short Interest Risk
Trip ifShort interest rises above 20% of float for more than 60 consecutive days.